







YOUR EYES, OUR VISION YOUR HEALTH, OUR MISSION











#### **NO MORE waiting**



© 2017 All rights reserved to ATI

Home Privacy Policy Terms of Use Contact us on:



#### **FIM**

#### The world's first pupil dilation device

ATI introduces FIM, the world's first pupil dilation device. Unlike dilation drops, FIM achieves full dilation in less than two minutes and recovery within minutes, dramatically improving the examination experience.



© 2017 All rights reserved to ATI

Home Privacy Policy Terms of Use Contact us on:




### The Pitch

**ATI** introduces an innovative device

"FIM 2<sup>nd</sup> Generation"

Dilates Eye Pupils, faster and safer, without the need for dilating eye substances.





# The Company

Offices located in Ra'anana, Israel

IP: Patents IL167559, US 11/909,103,, JPN 2007-555773

CE Mark & ISO 13485: FIM CE Mark & ISO approval since 2012

Received Israel Ministry of Health "AMAR" approval.



# The Team

Professor Liora Katzenstein	- Chair Person	
Mr. Tomas Mendelsohn	- Co-Founder , BoD Director & CEO	
Mr. Ilan Ron	- Co-Founder & VP R&D	
Mr. Yaacov Cohen	- BoD Director	
Mr. Yoram Wilamovsky	- BoD Director	
Prof. David Varsano - MD.	- Chief Medical Officer	



### **Mydriatics Today - The Problem**

#### **Time consuming:**

- Slow dilatation onset: up to 20-30 minutes often a repeat application is necessary.
- Slow eye recovery: up to 8 hours sometimes as long as 72 hours.

#### **Discomfort:**

- Irritated, red and stinging eyes, blurred vision.
- Unable to read, work or drive for 4-6 hours.

Risks: Provocation of Acute Glaucoma, Allergic Reactions, Eye Infection

The use of eye drops is time consuming for both patient and physician and has inherent side effects



#### FIM (Field Induced Mydriasis)

The FIM dilates the pupil by the creation of a low emission electromagnetic (EM) field.

When the FIM device is switched on, dilation starts immediately.

When switched off, the pupil returns to 80% of its normal size in less than 2 minutes.

Emitted EM fields are well within medical device safety standards.

No side effects or any type of discomfort, common when using drops. Speeds up eye exams, enabling physicians to see many more patients.



#### FIM (Field Induced Mydriasis)

ATI already developed FIM 2<sup>nd</sup> Generation first prototype

The FIM 2<sup>nd</sup> Generation will be more robust than its predicate device

A new era in ophthalmic eye treatment


No side effects or any type of discomfort, common when using drops. Speeds up eye exams, enabling physicians to see many more patients.



#### The FIM Device - 1st Generation



FIM Device



FIM 1st Generation Attached to Slit Lamp



### Advantages

Non-contact and non-invasive, easy to operate & use

Fast dilation onset: immediate (30-120 seconds)

Fast eye recovery: immediate (30-120 seconds)


No discomfort or side effects:

Immediately after eye examination, patient is able to read, work and drive.

The innovative & advanced FIM technology saves both physician and patient time and eliminates the side effects when using eye drops



#### Case Study



A fundus examination requires a pupil size of  $\geq 4$  - 4.5 mm. In this particular case this was achieved with the FIM in 120 seconds.



# **Competitive Comparison**

		Eye Drops	FIM Device
	Dilation onset	20-30 minutes	Seconds after start
	Recovery rate	Up to 8 hours	Less 2 minutes
	Post-exam effects	Blurred vision, stinging, red eyes, unable to work or drive up to 8 hours	None
	Elderly	Difficult to use	Easy to use
	Patient safety	Provocation of acute glaucoma, allergic reactions, eye, infections	No side effects

Without side effects: patient comfort and safety improve. With shorter exam times: more patients can be seen.



## Going to Market

### Launch strategies:

International Business
Development & Marketing
focused on:

Establishing a distribution network

Strategic partnerships (OEMs)

2<sup>nd</sup> Gen.

FIM Launch

2<sup>nd</sup>. Q. 2023



# Annex A: - Regulation & Validation

The FIM 1st G. device passed safety and EMC tests of the Israel Standard Institute.

The FIM 1st G. received European CE approval and complies with received certification of ISO Standard 13485.

ATI received Israel's Ministry of Health "AMAR" certification.

Expects to submit to the FDA in 2023 in the USA

Proof of concept & proof of market have been established.



#### Annex B: AMAR - CE Mark + ISO 13485









High Standards & Quality



### Summary



The "FIM" - An eye pupil dilating Medical Device & Technology, minimizes the waiting time and overcomes the drops side effects.

It replaces the use of eye drops with a non-contact, noninvasive device without changing the medical practice.

There is currently no such device/technology except from ATI.

To achieve our objectives for 2023 we seek a total investment of 2.5m\$ for the FIM 2<sup>nd</sup> Generation.

(Based 1 US\$ = 4.00 Nis)



# Thank You

For More Information Please contact:

Tomas Mendelsohn, CEO Mobile: +972-52-6167777

Office: +972-9-7467771

mailto: tomasm@ati-amt.com